Supplement Material from Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer
Authors: Cui Yi , Li Bailiang , Pollom Erqi L. , Horst Kathleen C. , Li Ruijiang 
Published: April 2023

<p>Supplement Table 1. Genes and Cox regression coefficients in radiation-sensitivity signature Supplement Table 2. Univariate and multivariate Cox regression analysis of local recurrence-free survival using RSS and clinical variables in the prognostic biomarker training cohort (GSE30682). Supplement Table 3. Univariate and multivariate Cox regression analysis of the interaction effect with radiation treatment using IMS and clinical variables in the predictive biomarker training cohort (E-TABM-158). Supplement Table 4. Number of patients excluded in the METABRIC cohort during variable matching and the reason for exclusion. Supplement Table 5. Multivariate Cox regression analysis of the interaction effect with radiation treatment using RSS and clinical variables in the entire METABRIC cohort. Supplement Table 6. Multivariate Cox regression analysis of the interaction effect with radiation treatment using IMS and clinical variables in the entire METABRIC cohort. Supplement Table 7. Multivariate Cox regression analysis of the interaction effect with radiation treatment using the integrated signature (RSS+IMS) and clinical variables in the entire METABRIC cohort. Supplement Table 8. Multivariate Cox regression analysis of the interaction effect with radiation treatment using RSI and clinical variables on the entire METABRIC cohort. Supplement Table 9. Multivariate Cox regression analysis of the interaction effect with radiation treatment using OncotypeDX and clinical on the entire METABRIC cohort. Supplement Table 10. Multivariate Cox regression analysis of the interaction effect with radiation treatment using RSS, IMS, OncotypeDX, RSI, and clinical variables on the entire METABRIC cohort. Supplement Figure 1. Standardized log-rank test statistics at different cutoffs of RSS on GSE30682. Supplement Figure 2. Local recurrence-free survival stratified by RSS on the prognostic biomarker training cohort GSE30862. Supplement Figure 3. Standardized log-rank test statistics at different cutoffs of IMS on E-TABM-158. Supplement Figure 4. Disease-specific survival stratified by IMS on the predictive biomarker training cohort E-TABM-158. (A) immune-effective group; (B) immune-defective group; Pinteraction = 0.0007. Supplement Figure 5. Relapse-free survival stratified by IMS in the prognostic validation cohort: (A) NKI; (B) GSE2034. Supplement Figure 6. Kaplan-Meier plot of DSS for patients who had received radiation versus those who did not: (A) in the entire METABRIC cohort; (B) in the matched METABRIC cohort. Supplement Figure 7. Disease-specific survival stratified by RSS for patients with mastectomy on the METABRIC cohort. (A) Matched radiation-sensitive cohort; (B) matched radiation-resistant cohort; Pinteraction = 0.007. Disease-specific survival stratified by IMS for patients with mastectomy on the METABRIC cohort. (C) Matched immune-effective cohort; (D) matched immune-defective cohort; Pinteraction = 0.009. Supplement Figure 8. Disease-specific survival stratified by integrated RSS and IMS signature for patients with mastectomy on the METABRIC cohort. (A) Matched radiation-sensitive, immune-effective cohort; (B) matched radiation-resistant, immune-defective cohort; (C) matched radiation-resistant, immune-effective or radiation-sensitive, immune-defective; Pinteraction = 0.004. Supplement Figure 9. Disease-specific survival stratified by RSS for patients with BCS on the METABRIC cohort. (A) Matched radiation-sensitive cohort; (B) matched radiation-resistant cohort; Pinteraction = 0.54. Disease-specific survival stratified by IMS for patients with BCS on the METABRIC cohort. (C) Matched immune-effective cohort; (D) matched immune-defective cohort. Pinteraction = 0.15. Supplement Figure 10. Disease-specific survival stratified by integrated RSS and IMS signature for patients with BCS on the METABRIC cohort. (A) Matched radiation-sensitive, immune-effective cohort; (B) matched radiation-resistant, immune-defective cohort; (C) matched radiation-resistant, immune-effective or radiation-sensitive, immune-defective; Pinteraction = 0.36. Supplement Figure 11. Disease-specific survival stratified by RSI on the METABRIC cohort. (A) Matched low-RSI (< 25% quantile) cohort; (B) matched high-RSI (> 25% quantile) cohort; Pinteraction = 0.63. Supplement Figure 12. Disease-specific survival stratified by Oncotype DX on the METABRIC cohort. (A) Matched high-risk (> 30) cohort; (B) matched low-risk (< 30) cohort; Pinteraction = 0.52.</p>